Optiscan has been featured in The Mercury following the submission of a regulatory dossier to the U.S. Food and Drug Administration (FDA) for its InSpecta™ imaging device, marking a significant step toward entry into the US veterinary market.

The article highlights how the submission represents a key milestone in Optiscan’s expansion into veterinary medicine, positioning InSpecta as a real-time, non-invasive imaging solution designed to support clinicians across a wide range of animal care settings. It also outlines the scale of the US veterinary market opportunity and the growing demand for advanced imaging tools, particularly in areas such as oncology.

The feature notes that the FDA submission brings together Optiscan’s full body of work on InSpecta, including design, performance, workflow integration, and validation data, and signals the transition from development to formal regulatory review. It also supports the company’s strategy to build a repeatable regulatory pathway across its broader portfolio.

“This detailed document unambiguously demonstrated Optiscan’s ability to translate its complex imaging technology into a format suitable for regulatory review,” said Dr Camile Farah, Optiscan CEO and Managing Director.

“By introducing real-time, non-invasive imaging across the full spectrum of veterinary services, InSpecta has the potential to fill a critical gap and help transform the way millions of companion animals are treated,” he said.

The Mercury – Read the full article here.